Literature DB >> 27446532

MicroRNAs in hereditary diffuse gastric cancer.

Mayra-Cecilia Suárez-Arriaga1, Rosa-María Ribas-Aparicio2, Martha-Eugenia Ruiz-Tachiquín3.   

Abstract

In 2012, gastric cancer (GC) was the third cause of mortality due to cancer in men and women. In Central and South America, high mortality rates have been reported. A total of 95% of tumors developed in the stomach are of epithelial origin; thus, these are denominated adenocarcinomas of the stomach. Diverse classification systems have been established, among which two types of GC based on histological type and growth pattern have been described as follows: Intestinal (IGC) and diffuse (DGC). Approximately 1-3% of GC cases are associated with heredity. Hereditary-DGC (HDGC), with 80% penetrance, is an autosomal-type, dominant syndrome in which 40% of cases are carriers of diverse mutations of the CDH1 gene, which encodes for the cadherin protein. By contrast, microRNA are non-encoded, single-chain RNA molecules. These molecules regulate the majority of cellular functions at the post-transcriptional level. However, analysis of these interactions by means of Systems Biology has allowed the understanding of complex and heterogeneous diseases, such as cancer. These molecules are ubiquitous; however, their expression can be specific in different tissues either temporarily or permanently, depending on the stage of the cell. Due to the participation of microRNA in the processes of cellular proliferation, cell cycle control, apoptosis, differentiation and metabolism, these have been indicated to have a role in the development of cancerous processes, finding specific patterns of expression in different neoplasms, including GC, in which the microRNA expression profile is different in samples of non-cancerous versus cancerous tissues. A difference has been observed in the expression patterns of DGC and IGC. However, the role of microRNA in HDGC has not yet been established. The present study reviews the investigations that describe the participation of microRNA in the regulation of genes CDH1, RHOA, CTNNA1, INSR and TGF-β in different neoplasms, such as HDGC.

Entities:  

Keywords:  hereditary diffuse gastric cancer; hsa-miR-9; hsa-miR-92; let-7 family; miR-200 family; microRNA

Year:  2016        PMID: 27446532      PMCID: PMC4950232          DOI: 10.3892/br.2016.706

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  29 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 2.  Hereditary diffuse gastric cancer: What the clinician should know.

Authors:  Ryan Ying Cong Tan; Joanne Ngeow
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

3.  Elevated serum level and gene polymorphisms of TGF-beta1 in gastric cancer.

Authors:  Xue Li; Zhi-Chao Yue; Yun-Yan Zhang; Jing Bai; Xiang-Ning Meng; Jing-Shu Geng; Song-Bin Fu
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

4.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

5.  The Lin28/let-7 axis regulates glucose metabolism.

Authors:  Hao Zhu; Ng Shyh-Chang; Ayellet V Segrè; Gen Shinoda; Samar P Shah; William S Einhorn; Ayumu Takeuchi; Jesse M Engreitz; John P Hagan; Michael G Kharas; Achia Urbach; James E Thornton; Robinson Triboulet; Richard I Gregory; David Altshuler; George Q Daley
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

6.  Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research.

Authors:  Rebecca C Fitzgerald; Richard Hardwick; David Huntsman; Fatima Carneiro; Parry Guilford; Vanessa Blair; Daniel C Chung; Jeff Norton; Krishnadath Ragunath; J Han Van Krieken; Sarah Dwerryhouse; Carlos Caldas
Journal:  J Med Genet       Date:  2010-07       Impact factor: 6.318

7.  MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis.

Authors:  Chun-Ming Wong; Lai Wei; Sandy Leung-Kuen Au; Dorothy Ngo-Yin Fan; Yuan Zhou; Felice Ho-Ching Tsang; Cheuk-Ting Law; Joyce Man-Fong Lee; Xianghuo He; Jue Shi; Carmen Chak-Lui Wong; Irene Oi-Lin Ng
Journal:  Oncotarget       Date:  2015-05-30

8.  MiR-429 inhibits cells growth and invasion and regulates EMT-related marker genes by targeting Onecut2 in colorectal carcinoma.

Authors:  Yingnan Sun; Shourong Shen; Xiaoping Liu; Hailin Tang; Zeyou Wang; Zhibin Yu; Xiayu Li; Minghua Wu
Journal:  Mol Cell Biochem       Date:  2014-01-10       Impact factor: 3.396

9.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

10.  Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin.

Authors:  Julio Cesar Madureira de-Freitas-Junior; Sandra Carvalho; Ana M Dias; Patrícia Oliveira; Joana Cabral; Raquel Seruca; Carla Oliveira; José Andrés Morgado-Díaz; Celso A Reis; Salomé S Pinho
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

View more
  2 in total

1.  Hsa-let-7d-5p Promotes Gastric Cancer Progression by Targeting PRDM5.

Authors:  Xiang Gao; Huiqi Liu; Rong Wang; Mingyu Huang; Qiong Wu; Yang Wang; Wei Zhang; Yongnian Liu
Journal:  J Oncol       Date:  2022-07-07       Impact factor: 4.501

2.  Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation.

Authors:  Le-Gao Chen; Ying-Jie Xia; Ying Cui
Journal:  Oncol Rep       Date:  2017-05-24       Impact factor: 3.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.